All In Biotech

Drug Trial Radar · NCT07685808

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

A Phase 2, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, With Different Doses and Drug-Titration Algorithms in Participants Living With Overweight or Obesity

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Jul 28, 2026

Primary completion

Jan 21, 2028

Study completion Jan 21, 2028

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jul 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well

Conditions

  • Overweight or Obesity

Interventions

  • OlatorepatideDrug

    Administered per the protocol

  • PlaceboDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to approximately 60 weeks
  2. Severity of TEAEsTime frame: Up to approximately 60 weeks
  3. Percent change in body weightTime frame: From baseline to week 52

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • AMR Clinical - Mobile

    Mobile, Alabama · Recruiting

  • Diablo Clinical Research - Flourish Research

    Walnut Creek, California · Recruiting

  • Chase Medical Research

    Waterbury, Connecticut · Recruiting

  • Alliance for Multispecialty Research (AMR) Clinical Miami

    Doral, Florida · Recruiting

  • AMR Clinical - Fort Myers

    Fort Myers, Florida · Recruiting

  • AGA Clinical Trials

    Hialeah, Florida · Recruiting

  • Flourish Research, Nature Coast Clinical Research

    Inverness, Florida · Recruiting

  • Flourish Research, Jacksonville Center for Clinical Research

    Jacksonville, Florida · Recruiting

  • K2 Medical Research Maitland LLC, Main Office

    Maitland, Florida · Recruiting

  • The IMA Group, IMA Clinical Research St. Petersburg

    St. Petersburg, Florida · Recruiting

  • Charter Research LLC - The Villages

    The Villages, Florida · Recruiting

  • Clinical Site Partners, LLC DBA Flourish Research

    Winter Park, Florida · Recruiting

  • Charter Research LLC - Chicago

    Chicago, Illinois · Recruiting

  • Flourish Research, Ravenswood Rheumatology

    Chicago, Illinois · Recruiting

  • AMR Clinical - Chicago Oak Brook

    Oak Brook, Illinois · Recruiting

  • AMR Clinical Wichita

    Wichita, Kansas · Recruiting

  • AMR Clinical - Lexington

    Lexington, Kentucky · Recruiting

  • Velocity Clinical Research - Omaha

    Omaha, Nebraska · Recruiting

  • NYC Research Inc

    New York, New York · Recruiting

  • Rochester Clinical Research

    Rochester, New York · Recruiting

  • Tribe Clinical Research

    Greenville, South Carolina · Recruiting

  • Flourish Research, Legacy Oaks Tower

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.